Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
Active, not recruiting · Phase 2 · NCT05588843
Conditions: Colitis Ulcerative
At a glance
- Research payments reported, 2025
- $285,083
- U.S. investigators named
- 11
- Sites paid
- 11
- Planned or actual enrollment
- 187
About the trial
- Sponsor
- Sanofi
- Tested
- SAR443122 (drug), Placebo (drug)
- Dates
- Started 2022-11-25; completion 2026-12-02
- Results posted
- Not yet
This is a randomized, double-blind, placebo controlled, dose-ranging Phase 2 study. The primary objective is to evaluate the efficacy and safety of SAR443122 compared to placebo in participants with moderate to severe UC. Dose selection for further clinical development will be based on the multiple efficacy, safety and PK parameters. The study consists of 4 parallel arms (3 dose groups of SAR443122 vs placebo) to assess the efficacy and safety of SAR443122 in participants with moderate to severe UC. All participants will receive a total of 52 weeks (a 12-week induction treatment phase and a 40-week maintenance phase) of study treatment, except if treatment should be discontinued per inves…
From ClinicalTrials.gov, last updated 2026-04-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genzyme Corporation reported $285,083 in research payments for this study in 2025 (46 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jatinder S. Pruthi, M.D. Gastroenterology · Lancaster, CA
- Vasundhara Cheekati, M.D. Hospitalist · Lawrenceville, GA
- Ioannis Economou, M.D. Gastroenterology · Glenview, IL
- Christopher R. Bartalos, DO Gastroenterology · Lees Summit, MO
- Adekunle Adeoti, MD Specialist · Irvington, NJ
- Christian D. Stone, MD, MPH Gastroenterology · Las Vegas, NV
- Murray Orbuch, M.D. Gastroenterology · New York, NY
- Bincy P. Abraham, MD Gastroenterology · Houston, TX
- Pedro M. Arguello, M.D. Gastroenterology · Houston, TX
- Alan P. Glombicki, M.D. Obesity Medicine · Houston, TX
- William M. Pandak JR., M.D. Gastroenterology · Richmond, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Interspond LLC $72,253
- Om Research Llc $46,512
- Sanmora Bespoke Clinical Research Solution Llc $42,174
- The Methodist Hospital Research Institute Houston Methodist Research Institute $32,740
- Richmond Institute for Veterans Research $21,730
- Northshore University Healthsystem - Evanston Hospital, IL $20,000
- Medcare Pharma Llc $19,625
- Agile Clinical Research Trials LLC $12,800
- Pioneer Clinical Research Ny Llc $8,780
- Integrity Research Llc $6,069
- Bvl Clinical Research $2,400
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.